Despite the cessation of trials with Rova-T as an ADC approach using a PBD dimer to target DLL3, this remains a conceivable target in neuroblastoma and other neuroendocrine tumors due to its relatively restricted normal expression and moderate expression in preclinical PDX models. The gene discussed is DLL3; the disease is neuroblastoma.